NASDAQ: CYTK

Cytokinetics (CYTK) Stock Analysis & Forecast

Nov 13 close

$56.13−0.03 (−0.1%)

Gekko Brief

AI summaryNov 9 close

Cytokinetics moved this week on third-quarter results and fresh clinical data. The company reported revenue of $47.56 million, beating estimates by $5.82 million, with an EPS of -$1.37 against expectations, and analysts are now forecasting 2027 revenues of US$443.0 million. Additional data from the ACACIA-HCM trial for aficamten were presented at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions, showing favorable cardiac remodeling and improvements in patient-reported health status in nonobstructive HCM. A director separately disclosed a proposed sale of 5,000 shares.

The stock closed at $55.14, up 2.7% on the day, but remains below both its 50-day average of $65.34 and its 200-day average of $69.93, with the shorter average also below the longer one, consistent with a longer-run downtrend; the shares touched a 52-week low of $58.05 earlier in the week and sit near the 52-week low of $53.55. The GekkoIndex reading of 73.6 places the stock in the Buying zone. Price sits 31.9% below the Gekko Fair Value of $80.97.

Over the next 20 trading days, there is no scheduled earnings report, with the next date set for 23 February 2027, 100 days away. Smart-money activity over the past 90 days shows one Congressional buy and no sales. Seasonally, the next 20 trading days have averaged -3.3% over 5 years, rising in 2 of them, a pattern worth noting alongside the current gap to fair value.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Cytokinetics price vs fair value

$80.88$56.13Nov ’25May ’26Nov ’26
Close $56.13200-day averageGekko Fair Value $80.88

Cytokinetics quick facts

Market cap
$7.82B
P/E ratio
—
Forward P/E
117.7
EPS, TTM
−$6.02
Revenue, TTM
$113.3M
Profit margin
0%
Dividend yield
—
Beta
0.47
Volume
1.01M avg 1.97M
1-year return
−14.9%
Typical daily move
±5.2%
Typical 20-day move
±7.8%
50-day average
$64.11
200-day average
$69.78
Next earnings
Feb 23 after close
Shares outstanding
139.3M
52-week range
$53.55$88.31

Cytokinetics swing-trade checklist

Cytokinetics scores 3 supportive, 1 mixed and 2 headwinds across the 6 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

3 supportive1 mixed2 headwinds

  • Trendheadwind

    Below 50 and 200-day

    Close $56.13 is below the 50-day ($64.11) and 200-day ($69.78) averages, and the 50-day is below the 200-day.

    See the chart
  • GekkoIndexsupportive

    64.9, Accumulation

    Reading 64.9 is in the Accumulation zone.

    See the GekkoIndex
  • Fair valuesupportive

    30.6% below

    Price is 30.6% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneymixed

    Mixed

    Last 90 days: Congress 1 buy / 0 sales. Last 30 days: 1 unusual options signal.

    See smart money
  • Earnings risksupportive

    Reports in 100 days

    Next report Feb 23, 2027, 100 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalityheadwind

    −1.8% on average

    From this point in the calendar, the next 20 trading days averaged −1.8% over 5 years, rising in 2 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Cytokinetics stock chart and price history

Cytokinetics closed at $56.13 on Nov 13, 2026, −14.9% over the past year, inside a 52-week range of $53.55 to $88.31.

Close50-day average200-day averageVolume
Cytokinetics share price, past year, with 50-day and 200-day moving averages and volume$50$60$70$80DecJan 2026FebMarAprMayJunJulAugSepOctNov56.13

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
−12.2%
3 months
−26.0%
6 months
−26.0%
1 year
−14.9%
The full CYTK chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open CYTK in Gekko

Follow Cytokinetics through every session

Put CYTK on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track CYTK in GekkoFree for 7 days. No credit card required.

About Cytokinetics

Cytokinetics is a biopharmaceutical company centered on muscle activators and muscle inhibitors designed to treat serious, debilitating conditions in the United States. It has brought to market MYQORZO, an oral small molecule that inhibits cardiac myosin and is used for symptomatic oHCM, and this is the therapy for which the company is best recognized.

Beyond its marketed product, the company's pipeline includes Aficamten, another oral cardiac myosin inhibitor aimed at HCM, and omecamtiv mecarbil, which is being studied as a possible treatment spanning various stages of heart failure with severely reduced ejection fraction. It is also advancing Ulacamten, an oral cardiac myosin inhibitor intended to ease hypercontractility linked to heart failure with preserved ejection fraction, along with CK-089, a fast skeletal muscle troponin activator, with both of these in Phase 1 clinical trials.

The company was incorporated in 1997 and operates out of South San Francisco, California. Its shares trade on the NASDAQ under the ticker CYTK.

Listed
NASDAQ
Sector
Health technology
Industry
Pharmaceuticals: major
Website
cytokinetics.com

Cytokinetics GekkoIndex: the smart money zone

Cytokinetics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 64.9, in the Accumulation zone, down 12.2 points over five sessions.

010064.9Accumulation

Down 12.2 points over five sessions, from the Buying zone.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying43+2.9%+2.6%+2.9%+2.4%
Accumulation (current zone)287+0.7%+0.4%−1.9%−3.0%
Neutral346−0.9%−0.5%+1.0%+3.8%
Distribution24−0.4%−2.8%−0.3%+4.9%
Selling2Too few readings yet

Average CYTK share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.

Accumulation zone: Institutional interest building. About the five zones →

See every daily GekkoIndex reading plotted over the CYTK price, zone by zone.Track CYTK in Gekko

Is Cytokinetics stock overvalued? Gekko Fair Value

Cytokinetics trades 30.6% below Gekko Fair Value of $80.88, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what Cytokinetics shares are worth, recalculated every trading day.

$80.88

Gekko Fair Value, Nov 14, 2026

30.6% Undervalued

At the end of Aug 2026 the price was 28.6% below the estimate.

Gekko Fair ValueShare price, month end
$81$56Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open CYTK in Gekko

Cytokinetics insider and Congress trading

No open-market insider purchases were filed for Cytokinetics, and members of Congress disclosed 1 purchase and 0 sales, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for CYTK in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every CYTK insider filing, plotted on the chart in Gekko.Open CYTK in Gekko

Congress trades last 90 days

1trade disclosed: 1 purchase and 0 sales.

MemberTypeAmountDisclosed
Gilbert Cisneros
House, CA, purchase
Purchase$1,001 - $15,000Oct 12
traded Sep 29

From congressional disclosures, which report amounts as ranges.

Buybacks

Cytokinetics has been buying back its own shares.

Bought back, quarter ended Sep 30, 2025
$21.33M
As a share of market cap
0.27%

From company filings.

Unusual options activity last 30 days

1signal, 0% of the flagged premium in calls.

Latest: Bullish flow on Nov 12, $338K in unusual premium.

Hedge funds and billionaires quarter ended Jun 30

1of the funds Gekko tracks holds CYTK.

0added0opened1trimmed0sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko

Cytokinetics earnings: next date and track record

Cytokinetics reports on Feb 23, 2027, after the close (100 days away), and beat the EPS estimate in 5 of its last 8 reports.

5 of 8reports beat the EPS estimate
±6.3%average move across the report
2 of 8reports followed by a gain

Share-price move across each report

−1.8%Feb ’25−9.9%May ’25−2.9%Aug ’25+1.1%Nov ’25−7.9%Feb ’26+13.3%May ’26−2.7%Aug ’26−10.8%Nov ’26

Last earnings call, Nov 4, 2026 AI summary

What they said
Cytokinetics reported Q3 2026 net revenue of $44.5M for MYQORZO, up 76% from Q2, with 2,800+ patients dispensed and nearly 1,100 unique prescribers. NBRx market share approached 45% in the CMI category. The company is advancing aficamten for nHCM with an sNDA submission planned this quarter, following positive ACACIA-HCM results published in NEJM. Pipeline programs including omecamtiv mecarbil and ulacamten also progressed.
Guidance
Cytokinetics expects to submit the nHCM supplemental NDA this quarter and an EMA application in early 2027. U.K. MYQORZO launch planned for Q4 2026, with additional country launches in 2027. PDUFA date for MAPLE-HCM data is November 14.
ReportedEPSSurpriseRevenueSurpriseMove
Nov 4, 2026−$1.37
est −$1.43
+4.2%$47.56M
est $41.88M
+13.6%−10.8%
Aug 6, 2026−$1.50
est −$1.63
+8.0%$28.62M
est $17.59M
+62.7%−2.7%
May 5, 2026−$1.67
est −$1.65
−1.2%$19.36M
est $8.52M
+127.2%+13.3%
Feb 24, 2026−$1.50
est −$1.56
+3.8%$17.76M
est $6.93M
+156.3%−7.9%
Nov 5, 2025−$1.54
est −$1.59
+3.1%$1.94M
est $6.05M
−68.0%+1.1%
Aug 7, 2025−$1.12
est −$1.34
+16.4%$66.77M
est $2.07M
+3,131.1%−2.9%
May 6, 2025−$1.36
est −$1.36
0.0%$1.58M
est $2.79M
−43.4%−9.9%
Feb 27, 2025−$1.26
est −$1.17
−7.3%$16.93M
est $14.26M
+18.7%−1.8%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Cytokinetics stock forecast and analyst price targets

Analysts’ average 12-month price target for Cytokinetics is $109.42, +94.9% from the last close, from 17 firms rating the stock in the last 90 days.

$109.42consensus 12-month target, +94.9% from the last close
Low $78High $140
Buy16
Hold1
Sell0

Each firm’s latest rating in the last 90 days: 17 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 9H.C. WainwrightBuy, reiterated$140+149.4%
Nov 6Truist FinancialBuy, reiterated$112+99.5%
Nov 6CitiBuy, maintained$105+87.1%
Nov 5Leerink PartnersBuy, reiterated$100+78.2%
Nov 5Stifel NicolausBuy, maintained$108+92.4%
−1.9%average 20-day move after past Accumulation readings
−1.8%average move over the next 20 trading days in the last 5 years
±5.2%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Cytokinetics seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Cytokinetics averaged −1.8% across the last 5 years, rising in 2 of them.

Next 20 trading days, by year

−5.3%2021+3.9%2022+9.0%2023−11.1%2024−6.4%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−3.1%2 of 5
Next 10 trading days−2.3%2 of 5
Next 15 trading days−5.5%0 of 5
Next 20 trading days−1.8%2 of 5
Next 30 trading days+30.5%3 of 5

For scale, CYTK’s typical 20-trading-day move in either direction is about 7.8%.

Cytokinetics market cap and key statistics

Cytokinetics’s market cap is $7.82B and revenue of $113.3M over the last twelve months.

Valuation

Market cap
$7.82B
Forward P/E
117.7
EPS, TTM
−$6.02
Gekko Fair Value
$80.88

Trading

Volume
1.01M
Avg volume, 20 days
1.97M
52-week high
$88.31
52-week low
$53.55
Shares outstanding
139.3M

Financials

Revenue, TTM
$113.3M
Profit margin
0%
Return on equity
-572%
Quarterly earnings growth, YoY
0.0%

Risk and income

Beta
0.47
Typical daily move
±5.2%
Typical 20-day move
±7.8%

Cytokinetics stock news this week

Coverage of Cytokinetics this week reads neutral: 4 positive, 5 neutral and 2 negative headlines.

News sentiment neutral

Cytokinetics peers

Cytokinetics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
LLYEli Lilly+1.0%Neutral24.0% above
JNJJohnson & Johnson+0.3%Neutral4.4% above
ABBVAbbVie−0.5%Neutral23.7% above
MRKMerck+0.3%Neutral8.2% below
AZNAstraZeneca−0.2%Neutral34.6% below
PFEPfizer−0.1%Accumulation8.9% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Pharmaceuticals: major

Cytokinetics stock FAQ

What is Cytokinetics’s market cap?

Cytokinetics’s market cap is $7.82B at the Nov 13, 2026 close of $56.13, with 139.3M shares outstanding.

What is the Cytokinetics stock forecast?

The consensus analyst 12-month price target for Cytokinetics is $109.42, +94.9% from the last close. Of the 17 firms that rated the stock in the last 90 days, 16 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Cytokinetics stock overvalued or undervalued?

On Gekko’s estimate Cytokinetics is undervalued: the Nov 13, 2026 close of $56.13 is 30.6% below Gekko Fair Value of $80.88. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Cytokinetics report earnings next?

Cytokinetics is expected to report on Feb 23, 2027, after the market closes (100 days away). Analysts expect earnings of −$1.41 per share on revenue of $64.28M. Cytokinetics beat the earnings estimate in 5 of its last 8 reports, moving 6.3% on average across the report.

What is Cytokinetics’s 52-week high and low?

Cytokinetics’s 52-week high is $88.31 and its 52-week low is $53.55; it closed at $56.13 on Nov 13, 2026, −14.9% over the past year. Over the last five years the shares peaked at $110.25 on Jan 8, 2024.

Is Cytokinetics stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 6 items with data read as supportive (gekkoindex, fair value and earnings risk), 1 as mixed (smart money) and 2 as headwinds (trend and seasonality). The checklist is a description of current data, not a recommendation.

Is there unusual options activity in Cytokinetics?

Gekko flagged 1 unusual options signal in Cytokinetics over the last 30 days, with $0 of flagged premium in calls and $338K in puts. The latest, bullish flow, was on Nov 12, 2026 with $338K in unusual premium. The signal-by-signal table is in Gekko.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Cytokinetics the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.